Perpetual Ltd decreased its holdings in Boston Scientific Co. (NYSE:BSX – Free Report) by 13.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,602 shares of the medical equipment provider’s stock after selling 1,359 shares during the quarter. Perpetual Ltd’s holdings in Boston Scientific were worth $465,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Householder Group Estate & Retirement Specialist LLC purchased a new stake in shares of Boston Scientific during the first quarter valued at $26,000. Asset Dedication LLC grew its position in Boston Scientific by 109.5% during the 1st quarter. Asset Dedication LLC now owns 551 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 288 shares in the last quarter. Sunbelt Securities Inc. acquired a new stake in Boston Scientific during the 1st quarter valued at $32,000. BerganKDV Wealth Management LLC grew its stake in Boston Scientific by 44.3% during the 1st quarter. BerganKDV Wealth Management LLC now owns 658 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 202 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of Boston Scientific in the 1st quarter valued at about $35,000. Institutional investors and hedge funds own 89.11% of the company’s stock.
Boston Scientific Trading Down 0.7 %
Shares of BSX stock opened at $53.60 on Monday. The company has a current ratio of 1.29, a quick ratio of 0.80 and a debt-to-equity ratio of 0.46. Boston Scientific Co. has a 1 year low of $37.74 and a 1 year high of $55.38. The firm’s fifty day simple moving average is $52.35 and its 200 day simple moving average is $51.81. The firm has a market capitalization of $78.48 billion, a P/E ratio of 89.33, a price-to-earnings-growth ratio of 2.10 and a beta of 0.78.
Insiders Place Their Bets
In other news, EVP Arthur C. Butcher sold 6,600 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $50.40, for a total transaction of $332,640.00. Following the sale, the executive vice president now directly owns 11,396 shares in the company, valued at $574,358.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 15,867 shares of the stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $55.00, for a total transaction of $872,685.00. Following the completion of the transaction, the executive vice president now directly owns 197,992 shares in the company, valued at $10,889,560. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 6,600 shares of the business’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $50.40, for a total transaction of $332,640.00. Following the completion of the sale, the executive vice president now owns 11,396 shares in the company, valued at approximately $574,358.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 217,635 shares of company stock worth $11,566,176. 0.71% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on BSX shares. Mizuho boosted their price objective on shares of Boston Scientific from $56.00 to $60.00 and gave the company a “neutral” rating in a research report on Thursday. Canaccord Genuity Group increased their price objective on Boston Scientific from $62.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday. Evercore ISI restated an “outperform” rating and issued a $60.00 target price on shares of Boston Scientific in a research note on Tuesday, September 19th. TheStreet raised Boston Scientific from a “c+” rating to a “b” rating in a research note on Tuesday, May 30th. Finally, BTIG Research boosted their price target on Boston Scientific from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday. Two analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $60.10.
Check Out Our Latest Report on Boston Scientific
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Featured Articles
- Five stocks we like better than Boston Scientific
- What is a Bond Market Holiday? How to Invest and Trade
- 3 Reasons This Sleeping Giant Is About To Wake Up
- 3 Monster Growth Stocks to Buy Now
- MarketBeat Week in Review – 9/18 – 9/22
- How to Invest in Music Stocks
- 52-week Low Names To Tip The Upside Scale In Your Favor
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
